A research on imaging of concentration of drug on the skin rash and normal skin tissue in patients with advanced pancreatic cancer treating with gemcitabine and erlotinib.

A research on imaging of concentration of drug on the skin rash and normal skin tissue in patients with advanced pancreatic cancer treating with gemcitabine and erlotinib. - A research on imaging of concentration of drug on the skin rash and normal skin tissue in patients with advanced pancreatic cancer treating with gemcitabine and erlotinib.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016297

Enrollment

Registered

2015-01-21

Start date

2013-10-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced pancreatic cancer

Interventions

Biopsy for all the enrolled subjects

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with histological or cytological evidence of pancreactic cancer(exclude of neuroendocrine tumor). Or, cytology is class 4, but clinically diagnosed pancreactic cancer. 2) Unresectable locally advanced or metastatic pancreatic cancer. 3) Patients aged more than 20. 4) Eastern Cooperative Oncology Group performance status of 0, 1 5) Patients treating witn erlotinib. 6) Patients who have adequate hematological, renal and respiratory, heart function. a) Neutrophil count is more than 500/mm3. b) Platlet is more than 50000/mm3 on the day of biopsy. 7) Informed consent can obtain from patients.

Exclusion criteria

Exclusion criteria: 1) In cases of difficult to biopsy of normal skin tissue, because of past history of skin disease, for example, atopic dermatitis or collagenosis. 2) Patients with past history of allergy of local anesthetization drug. 3) In cases of doctor judged inappropriate for this protocol.

Design outcomes

Primary

Measure	Time frame
Imaging of drug concentration of erlotinib on the skin tissue	—

Secondary

Measure	Time frame
To compare of imaging of drug concentration on skin rash and normal skin	—

Countries

Japan

Contacts

Public ContactMeiko Nishimura

Kobe University Hospital Department of Medical Oncology and Hematology

meinishi@med.kobe-u.ac.jp078-382-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026